RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I think your estimate of what the RD upfront would be is low. Although the focus of the study in question is for an acute indication, it is not lost on anyone that if ampakines rescue breathing in the acute indication, they are good candidates to mitigate the risk of opiate-induced RD in the context of chronic pain management. This is a much bigger market.

Although the regulatory hurdles facing ampakines in a chronic indication are different from those in an acute indication, I nonetheless think that for companies in the lucrative opioid analgesia market, ampakines would be of considerable interest, particularly in the absence of analgesia-sparing alternatives. Because there is more than one company in this market, they will be bidding against each other.

I have no idea at all what is going to happen to COR over the next year. It is worth noting though that when this board reaches a consensus based on echo rather than news, the consensus is reliably wrong.